Nuvasive (NUVA) 8-K Nuvasive Reports Fourth Quarter

Exhibit 99.1

PRESS RELEASE

NUVASIVE REPORTS FOURTH QUARTER

AND FULL YEAR 2013 FINANCIAL RESULTS

• Fourth quarter 2013 total revenue of $190.8 million; up 15.1% from fourth quarter 2012

• Full year 2013 total revenue of $685.2 million; up 10.5% from full year 2012

• GAAP operating margin of 7.9% for the fourth quarter 2013 and 4.8% for the full year 2013

• Non-GAAP operating margin of 16.3% for the fourth quarter 2013 and 14.9% for the full year 2013

• GAAP net earnings of $6.0 million, or $0.13 per share, for the fourth quarter 2013 and GAAP net earnings of $7.9 million, or $0.17 per share, for the full year 2013

• Non-GAAP earnings of $17.8 million, or $0.37 per share, for the fourth quarter 2013 and $57.4 million, or $1.23 per share, for the full year 2013

SAN DIEGO, March 3, 2014-NuVasive, Inc. (Nasdaq: NUVA) a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today financial results for the quarter and for the full year ended December 31, 2013.

Alex Lukianov, Chairman and Chief Executive Officer, said, “2013 results clearly demonstrate that NuVasive’s market share taking strategy is thriving. Importantly, we are cultivating the drivers that will support top and bottom line growth for many years to come. We are leveraging our unrivaled years of experience and research to continue championing the global market conversion toward less invasive spine solutions. And our commitment to innovation has conceived a pipeline that may dwarf all that we have accomplished so far. Onward and Upward!”

1

NuVasive reported fourth quarter 2013 revenue of $190.8 million, a 15.1% increase over the $165.8 million for the fourth quarter 2012 and a 12.8% increase over the $169.2 million reported for the third quarter 2013. The Company reported full year 2013 revenue of $685.2 million, a 10.5% increase over the $620.3 million reported for full year 2012.

Gross profit for the fourth quarter 2013 was $141.5 million and gross margin was 74.1%, compared to a gross profit of $123.6 million and a gross margin of 74.5% for the fourth quarter 2012. For the third quarter 2013, gross profit was $125.9 million and gross margin was 74.4%. Gross profit for the full year 2013 was $504.7 million and gross margin was 73.7%, compared to a gross profit of $466.8 million and gross margin of 75.3% for the full year 2012.

Total operating expenses for the fourth quarter 2013 were $126.4 million compared to $119.4 million in the fourth quarter 2012 and $114.3 million in the third quarter 2013. Full year 2013 operating expenses were $471.6 million compared to $429.8 million reported for the full year 2012. The higher operating costs for the fourth quarter and full year 2013 resulted primarily from spending to support international infrastructure expansion and higher revenue.

On a GAAP basis, the Company reported net income of $6.0 million, or $0.13 per share, for the fourth quarter 2013, and net income of $7.9 million, or $0.17 per share for the full year 2013.

On a Non-GAAP basis, the Company reported net income of $17.8 million, or $0.37 per share, for the fourth quarter 2013, and net income of $57.4 million, or $1.23 per share, for the full year 2013. The Non-GAAP earnings per share calculations for the fourth quarter and full year exclude, respectively, (i) non-cash stock-based compensation of $9.2 million and $33.2 million; (ii) certain intellectual property litigation expenses of $1.8 million and $5.7 million; (iii) amortization of intangible assets of $5.1 million and $19.3 million; (iv) acquisition related items of $42 thousand and $2.6 million; (v) non-cash interest expense on convertible notes of $3.5 million and $13.7 million; and (vi) a one-time out of period royalty expense charge related to royalty accruals in connection with Phase I of the company’s patent litigation with Medtronic of $7.9 million recorded in the second quarter 2013.

Cash, cash equivalents and short and long-term marketable securities were approximately $326 million at December 31, 2013.

2014 Full Year Financial Guidance

• Revenue of approximately $725 million;

• GAAP EPS of approximately $0.11;

• Non-GAAP EPS of approximately $1.06;

• Non-GAAP Operating Margin of approximately 16%;

• GAAP effective tax expense of approximately $19 million, which includes the impact of our Globalization Initiative

Supplementary Financial Information

For additional financial detail, please refer to the Supplementary Financial Information provided byCLICKING HERE or by visiting the Investor Relations section of our website atwww.nuvasive.com.

2

Reconciliation of Full Year EPS Guidance
		2014 Guidance  1
GAAP earnings per share		$	0.11
Non-cash stock based compensation			0.43
Certain intellectual property litigation expenses			0.06
Amortization of intangible assets			0.19
Leasehold termination charge			0.08
Acquisition related items 2			0.01
Non-cash interest expense on convertible notes			0.18
Non-GAAP earnings per share		$	1.06
Weighted shares outstanding - basic			47,500
Weighted shares outstanding - diluted			50,000
1 Effective tax expense rate of ~80% applied to GAAP earnings and 40% applied to Non-GAAP adjustments
2 Acquisition related items include expenses associated with prior M&A related activity and as incurred
Reconciliation of Non-GAAP Operating Margin %
	2013      Actuals	2014 Guidance
Non-GAAP Gross Margin % [A]	74.8%		76.0%
Non-cash stock based compensation	0.0%		0.0%
Out-of-period royalty expense charge	-1.1%		0.0%
GAAP Gross Margin [D]	73.7%		76.0%
Non-GAAP Sales, Marketing & Administrative Expense [B]	55.9%		54.5%
Non-cash stock based compensation	4.6%		4.8%
Certain intellectual property litigation expenses	0.8%		0.7%
Leasehold termination charge	0.0%		0.9%
Acquisition related items*	0.0%		0.1%
GAAP Sales, Marketing & Administrative Expense [E]	61.3%		61.0%
Non-GAAP Research & Development Expense [C]	4.1%		5.5%
Non-cash stock based compensation	0.2%		0.2%
Acquisition related items*	0.4%		0.1%
GAAP Research & Development Expense [F]	4.7%		5.8%
Amortization of intangible assets [G]	2.8%		2.2%
Non-GAAP Operating Margin % [A-B-C]	14.9%		16.0%
GAAP Operating Margin % [D-E-F-G]	4.8%		7.0%
* Acquisition related items include expenses associated with prior M&A activity and as incurred

3

Reconciliation of Non-GAAP Information

Management uses certain Non-GAAP financial measures such as Non-GAAP earnings per share, which exclude non-cash stock-based compensation, certain intellectual property litigation expenses, amortization of intangible assets, leasehold termination charge, acquisition related items, non-cash interest expense on convertible notes, and an out of period royalty expense charge. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the Non-GAAP financial measures provided in this earnings release excluding these costs and uses these Non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these Non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. These Non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from Non-GAAP measures used by other companies. Set forth below are reconciliations of the Non-GAAP financial measures to the comparable GAAP financial measure.

Reconciliation of Fourth Quarter 2013 Results
(in thousands, except per share data)	Pre-Tax   Adjustments		Net of Tax		Earnings Per   Share
GAAP net income			$	6,009	$	0.13
Non-cash stock-based compensation	$	9,238		5,542		0.12
Certain intellectual property litigation expenses		1,765		1,060		0.02
Amortization of intangible assets		5,063		3,037		0.06
Acquisition related items		42		24		0.00
Non-cash interest expense on convertible notes		3,508		2,106		0.04
Non-GAAP earnings			$	17,778	$	0.37
Weighted shares outstanding - diluted						47,947

Reconciliation of Full Year 2013 Results
(in thousands, except per share data)	Pre-Tax   Adjustments		Net of Tax		Earnings Per   Share
GAAP net income			$	7,902	$	0.17
Non-cash stock-based compensation	$	33,240		19,944		0.43
Certain intellectual property litigation expenses		5,728		3,437		0.07
Amortization of intangible assets		19,326		11,596		0.25
Acquisition related items		2,576		1,545		0.03
Non-cash interest expense on convertible notes		13,656		8,194		0.18
Out-of-period royalty expense charge		7,901		4,741		0.10
Non-GAAP earnings			$	57,358	$	1.23
Weighted shares outstanding - diluted						46,786

4

Conference Call

NuVasive will hold a conference call today at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available on our website, atwww.nuvasive.com in the Investor Relations Section.

After the live webcast, the call will remain available on NuVasive’s website through April 2, 2014. In addition, a telephonic replay of the call will be available until March 17, 2014. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use pin number 13574396.

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.

NuVasive offers a comprehensive spine portfolio of over 90 unique products developed to improve spine surgery and patient outcomes. The Company’s principal procedural solution is its Maximum Access Surgery, or MAS^® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry’s shift toward less invasive solutions. The Company’s dedication to innovation continues to spawn game changing technology such as the PCM^® motion preserving disc for the cervical spine, XLIF^® Corpectomy for tumor and trauma, and Armada^®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive’s solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up^TM; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation^®, and Absolute Responsiveness^®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive’s revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts; the risk of further adjustment to financial results or future financial expectations; unanticipated difficulty in selling products, generating revenue or producing expected profitability; and other risks and uncertainties more fully described in NuVasive’s press releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available atwww.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

5

###
Investor Contact:	Media Contact:
Tina Jacobsen	Nicole Collins
NuVasive, Inc.	NuVasive, Inc.
858-320-5215	858-909-1907
investorrelations@nuvasive.com	media@nuvasive.com

6

NuVasive, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

	Three Months Ended December 31,				Year Ended December 31,
	2013		2012		2013		2012
	(Unaudited)		(Unaudited)		(Unaudited)
Revenue	$	190,815	$	165,754	$	685,173	$	620,255
Cost of goods sold (excluding amortization of purchased technology)		49,353		42,196		180,484		153,409
Gross profit		141,462		123,558		504,689		466,846
Operating expenses:
Sales, marketing and administrative		113,821		97,713		420,064		372,416
Research and development		7,555		8,398		32,209		35,296
Amortization of intangible assets		5,063		3,600		19,326		12,430
Impairment of goodwill and intangible assets		-		9,700		-		9,700
Total operating expenses		126,439		119,411		471,599		429,842
Interest and other expense, net:
Interest income		195		254		755		915
Interest expense		(6,782)		(7,028)		(27,178)		(27,710)
Other income, net		164		901		3,101		1,047
Total interest and other expense, net		(6,423)		(5,873)		(23,322)		(25,748)
Income (loss) before income taxes		8,600		(1,726)		9,768		11,256
Income tax expense		2,763		1,050		2,783		8,814
Consolidated net income (loss)	$	5,837	$	(2,776)	$	6,985	$	2,442
Net loss attributable to noncontrolling interests	$	(172)	$	(30)	$	(917)	$	(702)
Net income (loss) attributable to NuVasive, Inc.	$	6,009	$	(2,746)	$	7,902	$	3,144
Net income (loss) per share attributable to NuVasive, Inc.:
Basic	$	0.13	$	(0.06)	$	0.18	$	0.07
Diluted	$	0.13	$	(0.06)	$	0.17	$	0.07
Weighted average shares outstanding:
Basic		44,820		43,628		44,461		43,328
Diluted		47,947		43,628		46,786		44,272

7

NuVasive, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

	December 31,
	2013		2012
ASSETS		(Unaudited)
Current assets:
Cash and cash equivalents	$	102,825	$	123,299
Short-term marketable securities		143,449		138,405
Accounts receivable, net		104,774		88,958
Inventory		136,937		126,364
Deferred tax assets, current		37,076		28,236
Prepaid expenses and other current assets		10,947		8,487
Total current assets		536,008		513,749
Property and equipment, net		128,064		125,123
Long-term marketable securities		79,829		84,412
Intangible assets, net		93,986		101,362
Goodwill		154,944		154,106
Deferred tax assets		42,863		40,575
Restricted cash and investments		119,195		118,995
Other assets		24,679		25,463
Total assets	$	1,179,568	$	1,163,785
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	86,057	$	62,048
Accrued payroll and related expenses		31,095		27,916
Senior Convertible Notes, current		—		74,311
Total current liabilities		117,152		164,275
Senior Convertible Notes		346,060		332,404
Deferred tax liabilities		2,934		3,129
Litigation liability		93,700		101,200
Other long-term liabilities		14,844		15,199
Commitments and contingencies
Noncontrolling interests		—		10,003
Stockholders’ equity:
Preferred stock		—		—
Common stock		45		44
Additional paid-in capital		769,203		714,865
Accumulated other comprehensive (loss) income		(3,238)		786
Accumulated deficit		(170,218)		(178,120)
Total Nuvasive, Inc. stockholders’ equity		595,792		537,575
Noncontrolling interests		9,086		-
Total equity		604,878		537,575
Total liabilities and equity	$	1,179,568	$	1,163,785

8

NuVasive, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Year Ended December 31,
	2013		2012		2011
	(Unaudited)
Operating activities:
Consolidated net income (loss)	$	6,985	$	2,442	$	(71,021)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		63,106		51,909		36,242
Deferred income tax (benefit) expense		(11,341)		4,525		(30,967)
Amortization of debt discount		13,656		12,697		6,108
Amortization of debt issuance costs		1,680		1,872		1,816
Stock-based compensation		33,240		26,312		32,070
Impairment of goodwill and intangible assets		—		9,700		18,167
Loss on repurchase of Senior Convertible Notes, net		—		—		332
Gain recognized on change in fair value of derivatives		—		—		(2,387)
Allowance for doubtful accounts and sales return reserves		959		103		1,345
Allowance for excess and obsolete inventory, net of write-offs		6,509		5,475		6,028
Other non-cash adjustments		7,116		7,283		6,227
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable		(17,384)		(2,005)		(9,929)
Inventory		(21,002)		(11,022)		(17,170)
Prepaid expenses and other current assets		(3,608)		12,725		(14,396)
Accounts payable and accrued liabilities		21,803		2,938		(3,385)
Litigation liability		(7,500)		—		101,200
Accrued payroll and related expenses		3,220		5,128		2,685
Net cash provided by operating activities		97,439		130,082		62,965
Investing activities:
Cash paid for business and asset acquisitions		(14,818)		(11,088)		(37,574)
Purchases of property and equipment		(47,597)		(41,189)		(53,370)
Purchases of marketable securities		(218,454)		(235,919)		(253,210)
Sales of marketable securities		216,299		246,504		151,966
Purchases of restricted investments		—		(113,281)		(4,536)
Sales of restricted investments		—		7,079		—
Payment for specific rights in connection with supply agreement, net of refund received		—		—		(5,000)
Net cash used in investing activities		(64,570)		(147,894)		(201,724)
Financing activities:
Proceeds from the sale of warrants		—		—		47,898
Proceeds from the issuance of convertible debt, net of issuance costs		—		—		391,445
Purchase of convertible note hedges		—		—		(80,097)
Principal payment of 2013 Senior Convertible Notes		(74,311)		—		—
Repurchase of 2013 Senior Convertible Notes		—		—		(154,164)
Tax benefits related to stock-based compensation awards		13,569		3,003		463
Proceeds from the issuance of common stock		8,422		4,884		6,852
Payment of contingent consideration		—		(29,722)		(1,800)
Other assets		(162)		(721)		(718)
Net cash (used in) provided by financing activities		(52,482)		(22,556)		209,879
Effect of exchange rate changes on cash		(861)		175		(225)
(Decrease) increase in cash and cash equivalents		(20,474)		(40,193)		70,895
Cash and cash equivalents at beginning of year		123,299		163,492		92,597
Cash and cash equivalents at end of year	$	102,825	$	123,299	$	163,492

9